Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Iniparib + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Iniparib | BSI-201|SAR240550 | Iniparib (BSI-201) appears to modify cysteine-containing proteins in tumor cells, and has minimal activity as a PARP inhibitor (PMID: 22128301, PMID: 22291137, PMID: 31172407, PMID: 30131387). | ||
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01593228 | Phase III | Carboplatin + Doxorubicin + Iniparib Iniparib + Paclitaxel Iniparib + Irinotecan Iniparib + Topotecan Carboplatin + Gemcitabine + Iniparib Iniparib | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | Completed | USA | ITA | ESP | BEL | 0 |